Old gout drug may keep heart in rhythm after valve surgery
NCT ID NCT04870424
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether colchicine, an anti-inflammatory drug used for gout, can prevent new-onset atrial fibrillation and the need for a permanent pacemaker in people undergoing transcatheter aortic valve replacement (TAVI). About 120 older adults with severe aortic stenosis were randomly assigned to receive colchicine or a placebo for 30 days after the procedure. The goal was to see if colchicine's anti-inflammatory effects could reduce common post-TAVI heart rhythm complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Colchicine
What this could lead to
If it works, this could offer a simple, inexpensive way to prevent common heart rhythm problems after valve replacement, reducing the need for a permanent pacemaker.
What could go wrong
This is a small, completed Phase 3 trial with 120 participants, so results may not apply to everyone. Colchicine can cause side effects like stomach upset, and its benefit here is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSCATHETER AORTIC VALVE REPLACEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Inselspital, Bern University Hospital, Department of Cardiology
Bern, 3010, Switzerland